Major Histocompatibility Complex Class II-restricted Presentation of an Internally Synthesized Antigen Displays Cell-type Variability and Segregates from the Exogenous Class II and Endogenous Class I Presentation Pathways

By George E. Loss, Jr.*, Chester G. Elias,† Patrick E. Fields,‡ Randall K. Ribaudo,§ Maureen McKisic,∥ and Andrea J. Sant‡

From the Departments of *Surgery and †Pathology, the University of Chicago, Chicago, Illinois 60637; and the Molecular Biology Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892

Summary

Although reported examples of endogenous antigen (Ag) presentation by major histocompatibility complex (MHC) class II molecules have increased, the mechanisms governing this process remain poorly defined. In this communication, we describe an experimental system designed to examine the mechanisms governing class II presentation of internal Ag. Our target peptide is processed from a transmembrane protein constitutively expressed by a variety of nucleated cells (MHC class I, H-2Lα), is naturally displayed by MHC class II molecules in vivo, and is recognized by a class II-restricted, CD4+ T cell hybridoma. Our results indicate that presentation of the Lα target Ag is independent of its plasma membrane expression, may not involve endosomal proteolysis, and thus may be distinct from the classically defined class II presentation pathway. In addition, the observations that Lα presentation does not require a functional TAP-1 complex, is not blocked by invariant chain, and cannot utilize cytoplasmic forms of H-2Lα, suggest that a classical class I pathway is not involved in this presentation event. Finally, our data suggest that different cofactors participate in MHC class II presentation of exogenous and endogenous Ag, and that disparate Ag presenting cells, such as B, T, and pancreatic islet cells, may differentially express these two class II pathways of Ag presentation.

T lymphocytes recognize Ag as peptide fragments associated with MHC molecules on the surface of APC (1, 2). MHC class II molecules have the specialized capacity to present peptides generated from extracellular Ag which enter the cell by endocytosis (3, 4). The resulting class II-peptide complexes, products of the endosomal-lysosomal processing pathway, are recognized by CD4+ T cells. In contrast, class I MHC molecules primarily present peptides derived from proteins with access to the cytosol and its resident proteolytic machinery. Resulting class I–peptide complexes are important in directing the immune response of CD8+ cytolytic T lymphocytes against virally infected cells.

It has become increasingly clear, however, that class II can efficiently bind and present peptides derived from proteins synthesized within the APC (5–13). This suggests that, in the absence of receptor-mediated uptake of extracellular protein, internally synthesized proteins may be the principal source of class II peptides. Like typical extracellular Ag, intracellular Ag could potentially access the endocytic processing pathway by internalization from the plasma membrane, by secretion and pinocytosis, or by receptor-mediated endocytosis. Internal Ag might also access the endosomal/lysosomal pathway by direct sorting from the trans-Golgi network (TGN)1, by heat shock protein (HSP)–mediated uptake from the cytosol (14), or by autophagy (15). Although the extent to which class II displays peptides derived from internally synthesized proteins is becoming increasingly apparent, the mechanisms governing their presentation remain poorly defined. Our understanding of class II presentation is largely derived from studies involving exogenous protein Ag. Interestingly, these studies have implicated the likely importance of several protein cofactors in class II Ag presentation including

1 Abbreviations used in this paper: ER, endoplasmic reticulum; GAM, goat anti-mouse Ig; gli, genomic invariant chain; hMYO, horse myoglobin; HSP, heat shock protein; Ii, invariant chain; MXH, mycophenolic acid, xanthine, and hypoxanthine; MYOT, tryptic digest of MYO; OVAT, tryptic digest of OVA; TGN, trans-Golgi network.
the invariant chain (Ii) (16), HSPs (17), and an as yet undefined protein(s) encoded by genes within the MHC (18). It is not known if the same protein cofactors will regulate the presentation of internal versus external Ag or if these cofactors will vary with cell type.

To examine the regulation of class II presentation of an intracellular Ag, we developed an experimental system in which a peptide processed from a MHC class I molecule (Ld) is displayed by the murine class II molecule I-A^d (19). The I-A^d/L^d peptide complex is recognized by a T cell hybridoma derived from the L^d-negative, BALB/c-H-2^dm-2 mouse. This system affords us the opportunity to examine presentation of a typical ubiquitous Ag which, under physiologic levels of expression, gains access to class II independently of an ongoing viral infection. Using recombinant DNA technology and cellular transfection techniques, we altered (a) subcellular localization of the class I target Ag; (b) lineage of the cell expressing both the target Ag and class II restriction element; and (c) expression of Ii within the APC, all parameters of potential relevance for Ag presentation and subject to variation in vivo. Collectively, our data suggest a pathway of endogenous class II Ag presentation, distinct from both the classically described class I and II presentation pathways, which may function selectively in the APC of different lineages.

Materials and Methods

Animals. BALB/c mice were purchased from the Jackson Laboratory (Bar Harbor, ME). H-2 L^d-negative BALB/c-H-2^dm-2 mouse (20) were bred at the University of Chicago in a barrier facility from stock provided by Dr. Roger Melvold (Northwestern University, Chicago, IL).

Tissue Culture Reagents. Cell lines were maintained at 37°C and 5% CO_2 in supplemented RPMI as described (21) plus selection drugs G418 (0.2 mg/ml), MXH (6 μg/ml mycophenolic acid, 0.3 mg/ml xanthine, and 15 μg/ml hypoxanthine) (Sigma Chemical Co., St. Louis, MO), and hirtidinol (5 mM) as indicated. All media and supplements were purchased from GIBCO BRL (Grand Island, NY) unless otherwise noted. The synthetic peptide corresponding to amino acids 61-85 of L^d was synthesized at the University of Chicago Cancer Center. Chicken OVA and horse myoglobin (hMYO) were purchased from Sigma Chemical Co. and tryptic digests of each (OVAT and MYOT, respectively) were prepared as described by Shimemonkevitz et al. (22). Purified soluble L^d/Q10 was prepared by L. Boyd and D. Margulies (National Institutes of Health [NIH]).

mAbs. mAb-producing hybridomas reactive with I-A^d (MKD6 [23], M5/114 [24], K24-199 [25], 40B [26]); I-E (14-4-4S [27]); I-A^d (10.2-16 [28]); H-2K^d (16.1.11N [25]); and with H-2L^d (30.5.7 [29], 28.14.8 [29]) were acquired from American Type Culture Collection (Rockville, MD). 64.3.7 (anti-L^d [30]) was provided by D. Sachs (NIH), whereas F23.1 (anti-TCR Vβ8 [31]) culture supernatants was kindly provided by J. Bluestone (University of Chicago). Ii-reactive mAbs (P4H5 [32], IN-1 [33]) were gifts from J. Miller (University of Chicago). The mAbs 2.43 (anti-CD8 [34]) and GKL1.5 (anti-CD4 [35]) were provided by F. Fitch (University of Chicago). Antibodies were used as culture supernatants except for in vivo T cell depletion experiments where an ascites preparation of 2.43 was used.

Flow Cytometry. Cells were evaluated for MHC molecule cell surface expression using mAb as culture supernatants and a secondary staining reagent (FITC-labeled goat anti-mouse Ig [FITC-GAM]; Cappel Laboratories, Cochranville, PA) as described (21), and analyzed on a FACScan® cytofluorimeter (Becton Dickinson & Co., Mountain View, CA). Background control fluorescence was measured using an irrelevant mAb plus FITC-GAM or medium alone and FITC-GAM (as indicated in each figure, see Results).

Gene Constructs. The L^d genomic clone pL^d.4 was kindly provided by T. Hansen (Washington University, St. Louis, MO) and pL^d/Q10 (36) was provided by D. Margulies. An L^d cDNA (37) was cloned into the Lk444 (38) vector utilizing the β-actin promoter (pLd444), and a leaderless L^d construct (pL^dovo) was generated from pL^d444 utilizing PCR mutagenesis to remove the sequence encoding the leader peptide from L^d and then adding an initiation sequence (39) 5' to the αα domain of H-2L^d. The altered L^d gene was sequenced and subsequently subcloned into the Lk444 β-actin expression vector.

Transfectants. The class II-negative cell line DAP.3 was transfected with I-A^d αα and β chain genes and the selection marker EcoRt by the calcium phosphate method (40) and selected in MxH. Supertransfection of I-A^d positive cells (DAP-AD) was subsequently performed using a second selection marker (pSV2neo) and either pL^d.4, pLd444, pL^d/Q10, or the pL^dovo construct. Cells resistant to G418 were then subcloned or sorted for cell surface expression of H-2L^d. DAP-LD and DAP-LD/Q10 were derived by transfection of DAP.3 with pL^d.4 or pL^d/Q10, respectively. Those cells transfected with pL^d/Q10 were subcloned by limiting dilution and screened for L^d/Q10 expression by immunoprecipitation and intracytoplasmic staining.

Ltk^- cells transfected with I-A^d only (LAD) or I-A^d plus genomic Ii (LADgIi) (41), the thymic tumor cell line EL4 transfected by electroporation with I-A^d and EcoRt (ELAD) (42), and a βTC-3 (H-2^b) insulinoma cell line transfected with I-A^d (β-AD) (43) were generously provided by J. Miller. LAD and LADgIi were subsequently transfected with genomic L^d and the selection marker pSV2/αα (44) by the calcium phosphate method yielding LAD-LD (MG1T) and LADgIi-LD (MG2T), respectively. Sublines were selected in MxH, G418, and hirtidinol. Transfectants matched for class II and L^d expression were obtained by mAb and magnetic bead cell sorting. The EL4 cell line (ELAD) was subsequently supertransfected with genomic L^d (pL^d.4) and pSV2/neo by electroporation, and the resulting cells (ELAD-LD) selected in G418 and MxH.

The embryonic cell line EE2H3 (H-2^b) originally derived by Silverman et al. (45) and provided by J. Bluestone was transfected with I-A^d, genomic L^d, and pSV2/neo by the calcium phosphate method. EE2H3-ADLD transfectants (GEE.4) were selected in G418 and sorted for I-A^d expression.

T Cell Lines and Hybridomas. The CD4^+ T cell clones 93.1 (I-A^d restricted, L^d peptide 61-85 specific) and 50.13 (H-2L^d restricted) were obtained from dm2 mice immunized with full thickness BALB/c skin grafts (19). T cell clones were fused with the hypoxanthine guanine phosphoribosyl transferase (HPRT) negative thymoma line αα ββ BW5147 by fusion with polyethylene glycol (PEG 1500; Boehringer Mannheim, Mannheim, Germany) (46). Hybridomas were selected with HAT (GIBCO BRL) and plated at limiting dilution. Hybridomas from the 93.1 clone (GTH) were screened on irradiated (2,000 rad) BALB/c splenocytes and DAP-ADLD transfectants for their ability to produce lymphokines, whereas those from 50.13 (EM50.13) were screened on A20 and DAP-LD.

A CD4^+ L^d-reactive bulk T cell population was generated by
immunization of CD8-depleted dm2 mice with irradiated BALB/c splenocytes. In vivo T cell depletion was performed as described (19) and CD8-depleted dm2 mice were then immunized intraperitoneally with 3 x 10^5 irradiated BALB/c splenocytes. 11 d after immunization, spleen cells from the dm2 mice were subjected to in vitro depletion using anti-CD8 mAb (2.43), anti-Ia mAbs (MKD6, K24-199, M5/114, 14.4.4S), and low-Tox-M rabbit complement (Cedarlane Laboratories Ltd., Hornby, ON, Canada). Appropriate cellular depletion was confirmed by flow cytometry. For stimulation of the dm2 anti-BALB/c bulk T cell population, 2.5 x 10^5 T cells were placed in microwells with 5 x 10^5 mitomycin-treated L cells or 5 x 10^5 irradiated splenocyte APC. After 48 h of incubation at 37°C, cultures were pulsed with 1 µCi/well of ^[3]H]thymidine and T cell proliferation was measured as a function of ^[3]H]thymidine incorporation. Cultures using L cells as APC were performed in the presence of the prostaglandin inhibitor indomethacin (5 µg/ml).

T Cell Hybridoma Assays. APC used at the concentrations indicated (see figures) and hybridomas used at 5-7.5 x 10^6 cells/well were cocultured for 16-20 h and supernatants tested for lymphokine content by culture with the growth factor-dependent T cell line CTLL as described (19). Results appear as mean cpm of triplicate cultures unless otherwise noted.

Cytokine Induction of MHC Expression. APC were treated for the times indicated with 10 U/ml of IFN-γ (Genzyme Corp., Cambridge, MA) and 100 U/ml of TNF (gift of Dr. Hans Schreiber, University of Chicago). Before initiation of the Ag presentation assay, APC were washed thoroughly and an aliquot of APC stained to evaluate cytokine-induced changes in surface MHC expression.

Coculture Assays. Irradiated dm2 or BALB/c splenocytes were incubated with L^d/Q10 containing supernatant as described (see Fig. 3 legend). Cell–cell coculture experiments were performed in 25 cm^2 culture flasks using equal numbers of DAP-AD and DAP-LD/Q10, as indicated (see Fig. 3 legend). L. Boyd and D. Margulis kindly provided us with purified L^d/Q10 and performed quantitative analysis of L^d/Q10 contained in supernatants from DAP-ADLD/Q10 and DAP-AD/Q10 cultures using an ELISA assay.

Metabolic Labeling, Immunoprecipitation, and SDS-PAGE. Metabolic labeling and immunoprecipitation of proteins from transfected cells was performed as previously described (47). Immunoprecipitated material was analyzed by SDS-10% PAGE. All SDS gels were dried, and autoradiographs prepared at -70°C.

Results
The T Cell Hybridoma GTH Maintains the Reactivity Pattern of the Parent T Cell Clone. We generated a T cell hybridoma from the clone 93.1 and α^C^β^-BW5147 (19). The use of a hybridoma diminishes the contribution of accessory molecules to T cell stimulation and provides a more direct method of assessing peptide–MHC complex expression. Fig. 1 demonstrates stimulation of one such T cell hybridoma (GTH) by L cells (DAP,3: H-2^b, class II^−) transfected with both the target Ag (L^d) and the I-A^d restriction element (DAP-ADLD). This response was specifically blocked by mAbs directed against I-A^d. GTH also produced lymphokines in response to a synthetic peptide of L^d (amino acids 61-85) added to either live or fixed I-A^d-bearing APC that lack L^d. These results establish that GTH is restricted by I-A^d and specific for a fragment of L^d, mirroring the reactivity of the parent dm2-derived T cell clone.

Cell Surface Expression of H-2L^d Is Not Required for Processing and Presentation by I-A^d. The most obvious route for an endogenously synthesized transmembrane Ag to gain access to the endocytic processing compartment is by internalization from the plasma membrane. To determine whether cell surface expression of L^d is required for processing and presentation of the L^d peptide, a gene encoding a soluble form of the target Ag (L^d/Q10) was transfected into DAP.3 with or without the I-A^d restriction element. L^d/Q10 (comprised of the NH2-terminal α1 and α2 domains of L^d and the α3 COOH-terminal domain of Q10 [36]) associates with β2 microglobulin, maintains normal α1 and α2 antibody epitopes, lacks a transmembrane domain, and is thus not expressed at the cell surface, but is secreted into the extracellular medium. Fig. 2 A shows metabolically labeled L^d/Q10 precipitated from whole L cell transfected lysates (lane 3) or from the extracellular medium (lane 9). As expected, L^d/Q10 was not detected at the cell surface by immunofluorescence staining (Fig. 3 D), nor was an L^d-restricted alloreactive T cell hybridoma (EM50.13) stimulated by L^d/Q10 transfectants (data not shown). Despite a lack of L^d surface expression, DAP-ADLD/Q10 transfecteds processed and presented the target L^d peptide to GTH as effectively as DAP-ADLD (Fig. 2 B).

To further test the possible involvement of a cell surface intermediate in L^d presentation, we sought to alter processing of L^d and L^d/Q10 with anti-L^d antibodies. If transient surface or extracellular expression of L^d is critical for generation of the GTH-specific peptide, then addition of anti-L^d antibody might be expected to modulate L^d Ag presentation. Despite using a broad panel of anti-L^d antibodies of
varying domain specificity and increasing antibody incubation times, no specific modulation of Ld Ag presentation was detected for either DAP-ADLD or DAP-ADLD/Q10 (data not shown).

Presentation of the Secreted Ld/Q10 Does Not Occur by Internalization from the Medium. To test the possibility that secreted Ld/Q10 enters the class II Ag processing compartment by reuptake from the extracellular medium, DAP-AD cells were incubated for 4 d, or irradiated dm2 splenocytes (spln) were incubated overnight, with supernatant (SN) containing Ld/Q10. Neither DAP-AD nor dm2 splenocytes stimulated GTH when pulsed with Ld/Q10 (Fig. 3, A and B). The Ld/Q10-containing supernatant used in these experiments was freshly obtained from confluent flasks containing DAP-ADLD/Q10 transfectants, and cells from these same flasks were effective stimulators of GTH (Fig. 3, A and B, shaded bars). Moreover, purified Ld/Q10 added to DAP-AD at a concentration 1,000-fold higher than that maximally accumulated in the medium of Ld/Q10-secreting cells did not stimulate GTH (Fig. 3 E). To test whether suboptimal levels of peptide-MHC complexes were expressed by DAP-AD in the presence of purified soluble Ld/Q10, we performed a dose-response assay using synthetic Ld 61-85 peptide. We reasoned that if a significant but subthreshold level of processed Ld peptide was displayed in the presence of high-dose Ld/Q10, then less Ld 61-85 peptide should be required to stimulate GTH. This should result in a shift to the left in the Ld 61-85 peptide dose-response curve. No such shift in the peptide dose-response curve was evident in the presence of exogenously added soluble Ld/Q10 (Fig. 3 E, △ vs □). These results strongly suggest that the epitope recognized by GTH is not readily generated after endocytosis of target Ag from the culture medium.

Although exposure of APC to extracellular Ld/Q10 did not result in detectable levels of GTH-specific peptide, we considered the possibility that cell-cell contact might facilitate Ld/Q10 uptake. To address this possibility, cells transfected with Ld/Q10 alone (DAP-ADLD/Q10) were cocultured with DAP-AD. APC from these mixed cultures did not stimulate GTH, indicating that presentation of the determinant recognized by GTH does not occur by uptake of Ld/Q10 from the medium or from adjacent cells (Fig. 3 B, open bar).

To test whether the secreted Ld Ag could serve as substrate for the generation of peptide epitopes other than that recognized by GTH, we generated a polyclonal dm2 anti-BALB/c CD4+ T cell population. As shown in Fig. 3 C, CD4+ T cells obtained from immunized dm2 mice were able to recognize and proliferate in response to I-Aα-bearing APC cocultured with either DAP-ADLD/Q10 cells or supernatant containing Ld/Q10. This suggests that a recognizable epitope(s) is generated from Ld/Q10 after endocytosis, and that this epitope is likely distinct from that generated from internally synthesized Ld/Q10.

In summary, our results using the Ld/Q10 construct indicate that cell surface expression of the target Ag is not required, nor is addition of the target Ag to the extracellular medium sufficient, for generation of peptide-class II complexes recognized by GTH. This suggests that the Ld peptide is generated during intracellular biosynthesis and transport of the newly synthesized target Ag. Thus, internally derived Ld either accesses the class II endosomal processing compartment with far greater efficiency than exogenous Ag, or it employs proteolytic machinery different from that used to process extracellular Ag taken up by endocytosis.

A Cell Line Deficient in Presentation of Exogenous Nominal Ag Efficiently Presents the Endogenously Derived Ld Peptide. To explore the possibility that Ld and exogenous Ag utilize distinct presentation pathways, we examined a cell deficient in exogenous Ag presentation for its ability to process and present...
endogenous L₄, exogenous L₄/Q₁₀, and synthetic L₄ 61-85 peptide. The lymphoblast tumor cell line ELAD (EL4 transfected with I-Aᵈ) (42) is unable to present exogenous Ag to OVA-specific hybridomas (Miller, J., unpublished observations, and 49). Fig. 4 A demonstrates the inability of ELAD to stimulate the hMYO-specific, I-Aᵈ-restricted T cell hybridoma ACHhMyo/27.7 in the presence of whole hMYO Ag. In the presence of MYOT, however, ELAD stimulated ACHhMyo/27.7 as effectively as DAP-AD (Fig. 4 B). We also found ELAD incapable of presenting exogenous nominal Ag to a panel of I-Aᵈ-restricted hybridomas while ELAD stimulated these same T cells when Ag processing was bypassed by providing peptide (data not shown). This indicates that the Ag presentation defect in ELAD is due to an intracellular processing event, not to a defect in class II or in accessory molecule function. We next examined the ability of ELAD to process and present purified L₄/Q₁₀. As shown in Fig. 5 D, ELAD could not utilize exogenously added purified L₄/Q₁₀ to generate peptide-MHC complexes sufficient for GTH stimulation. Moreover, no shift was observed when
Figure 4. EL4 cells transfected with I-A<sup>d</sup> cannot effectively process and present nominal Ag (A) but can present peptide (B). (A) ELAD and DAP-AD cells were incubated with 0.05 mg/ml of hMYO for 11 h, washed, fixed (0.1% paraformaldehyde x 20 min), and plated at varying numbers with 5 x 10<sup>4</sup> I-Ad-restricted, hMYO-specific T cell hybridomas (ACHhMYO/27.7). (B) ELAD and DAP-AD APC were fixed as in A and then incubated with (10 µg/ml) of MYOT in the presence of ACHhMYO/27.7. The number of APC per well was titrated while T cells were plated at 5 x 10<sup>4</sup> cells/well. T cell lymphokine production was measured by CTLL incorporation of [3H]thymidine.

Pancreatic Islet Cells Fail to Present Internally Synthesized L<sup>d</sup>. Our experiments using EL4 suggest that presentation of exogenous Ag by MHC class II is not a ubiquitous activity shared by all APC. We therefore examined a large panel of cells for the ability to present the L<sup>d</sup> to GTH to evaluate whether presentation of internally synthesized Ag is an activity universally shared by APC. One cell line tested, a pancreatic islet cell line (βTC-3 [H-2<sup>d</sup>]) transfected with I-A<sup>d</sup> (β-AD), can be induced to express high levels of MHC molecules upon treatment with IFN-γ and TNF (50, 51). The I-A<sup>d</sup> islet transfectant was grown for 5 d in the presence or absence of 10 U/ml IFN-γ and 100 U/ml TNF and stained with mAbs reactive with L<sup>d</sup> and I-A<sup>d</sup>. Fig. 6 A shows that in untreated cells (M), the L<sup>d</sup> surface staining is only slightly above background levels obtained with an irrelevant control mAb. In contrast, when cells are grown in the presence of cytokine, H-2L<sup>d</sup> expression increases 10–20-fold. High levels of L<sup>d</sup> surface expression were detected with both peptide-dependent (30-5-7) and -independent (28-14-8) anti-L<sup>d</sup> mAb (Fig. 6 A and data not shown) suggesting that the MHC class I presentation pathway is functional in the cytokine-treated cells.

We considered several possibilities to explain this result. First, staining profiles for ELAD-LD and DAP-ADLD using several anti-I-A<sup>d</sup> and anti-L<sup>d</sup> mAbs (Fig. 5 A) demonstrate that the two APC have comparable expression of both the restriction element and the target Ag. Second, it was possible that ELAD effectively presented L<sup>d</sup> because of an enhanced avidity of ELAD for the GTH hybridoma. But when Ag processing is bypassed through addition of synthetic L<sup>d</sup> 61-85 peptide, ELAD and DAP-AD are nearly equivalent APC for GTH (Fig. 5 B). Finally, we considered the possibility that stimulation of GTH occurred because of supersaturating amounts of L<sup>d</sup> peptide generated by the internal route of presentation. This excess would allow ELAD-LD to display peptides derived from internal L<sup>d</sup> at threshold levels for T cell stimulation compared to subthreshold levels from peptides derived from exogenous Ag. To more accurately quantify the efficiency of presentation, Ag presentation blocking experiments were performed using varying concentrations of anti-I-A<sup>d</sup> (M5114) mAb added to ELAD-LD or to control DAP-ADLD APC (Fig. 5 F). Parallel blocking studies were performed in L<sup>d</sup>-negative DAP-AD and ELAD cells using the L<sup>d</sup> 61-85 peptide (Fig. 5 E) to control for the adhesion/accessory properties of these APC. Antibody concentrations capable of effecting a 50% reduction in the maximal GTH response were then calculated for each APC. Based on these assays, we conclude that ELAD-LD processing and presentation of internally derived L<sup>d</sup> is in fact approximately threefold more efficient than DAP-ADLD (Fig. 5, E and F). These data argue against the possibility that EL4 transfectants present internal L<sup>d</sup> Ag, but not exogenous Ag, because endogenous Ag gain access to the class II presentation pathway more efficiently than exogenous Ag. These results, therefore, support our hypothesis that the L<sup>d</sup> peptide is generated by intracellular processing events that may differ from those typically used to process exogenous Ag.

To determine if ELAD can process and present internally derived L<sup>d</sup> peptide, ELAD cells were supertransfected with the gene encoding L<sup>d</sup> (ELAD-LD) and tested for their ability to stimulate GTH. As shown in Fig. 5 C, these cells efficiently stimulated GTH suggesting that events critical for class II presentation of internally synthesized L<sup>d</sup> are fundamentally different from those critical for class II presentation of exogenous Ag. A similar conclusion was recently reached by Bikoff (49) using this cell line.
Figure 5. ELAD-LD efficiently presents the endogenously derived Ld target Ag. (A) DAP-ADLD and ELAD-LD express similar surface levels of both I-A^d and Ld. DAP-ADLD (a and b) and ELAD-LD (c and d) were stained with anti-class II (a and c) and anti-Ld (b and d) mAbs. For a and c, cells were stained with the mAbs MKD6 (--), K24-199 (-----), and 40B (----). (b and d) Staining with the mAbs 30.5.7 (anti-Ld) (-----) and 64.3.7 (anti-Ld) (----). Background staining was performed using the irrelevant mAb 14.4.4S and FITC-GAM. (B) ELAD and DAP-AD APC, fixed to prevent Ag processing, stimulate GTH similarly in the presence of Ld 61-85 peptide. APC, fixed by incubation in 0.1% paraformaldehyde for 20 min, were plated at various cell concentrations with a constant number (5 x 10^4) of GTH T cells and 0.5 #M of Ld 61-85 peptide. (C) ELAD-LD stimulates GTH comparably to DAP-ADLD. ELAD, ELAD-LD, and DAP-ADLD were plated at various cell concentrations with 5 x 10^4 GTH T cells in an Ag presentation assay. (D) 5 x 10^4 ELAD APC were placed in an Ag presentation assay with increasing concentrations of purified Ld/Q10 (■) and examined for the ability to stimulate GTH. Peptide dose-response curves were generated using ELAD APC, and GTH T cells, and increasing concentrations of Ld 61-85 peptide in the presence (▲) or absence (□) of 0.05 #M Ld/Q10. (E) M5114 (anti-I-A^d) mAb was incubated at various concentrations with 5 x 10^4 APC, 5 x 10^4 GTH T cells, and a suboptimal dose of Ld 61-85 peptide (0.025 #M). Results are recorded as mean cpm of duplicate cultures. The initial M5114 dilution (10) corresponds to 100 #l of mAb culture supernatant in a final vol of 200 #l. Control cpm recorded in absence of M5114 are presented as points adjacent to the y-axis. (F) 5 x 10^4 of the indicated APC and 5 x 10^4 GTH T cells were incubated in an Ag presentation assay in the presence of decreasing concentrations of M5114. As in Fig. 5 E, the initial M5114 concentration was 100 #l culture supernatant in a final vol of 200 #l, and control data points (no mAb) are presented adjacent to the y-axis.

Untreated islet cells (β-AD [M]) did not stimulate GTH (Fig. 6 B) but did when provided with exogenously added Ld peptide, indicating that the islet cells express sufficient accessory molecules to effectively interact with the T cell hybridoma. To determine whether increased target Ag expression would permit β-AD to stimulate GTH, we induced Ld expression with IFN-γ and TNF. Time course experiments demonstrated that although islet cell Ld surface expression increased within 24 h of cytokine treatment, presentation of internally synthesized Ld did not occur even after 5 d of treatment (Fig. 6 B). Nor was a shift in the Ld 61-85 peptide dose-response curve observed after induction of Ld expression (Fig. 6 B). Control experiments demonstrated that TNF and IFN-γ treatment had no effect on β-AD exogenous Ag presentation (Fig. 6, C and D) and did not antagonize exogenous or endogenous Ag presentation in control APC (Fig. 6, E–H). From these experiments, we conclude that expression of endogenous Ld within the default exocytic pathway and at the cell surface is insufficient for presentation of the target peptide to GTH. Rather, these data suggest that presentation of internally synthesized Ag by class II requires protein cofactors in addition to MHC class II, and that these cofactors may be differentially expressed in different cell types.

Expression of a Leaderless Form of the Target Ag Does Not Result in Stimulation of GTH. Transmembrane viral Ag are proteolyzed in the cytosol and presented by class I molecules by a process that presumably employs a pool of viral Ag inefficiently translocated into the endoplasmic reticulum (ER) (52). Since presentation of Ld does not require either internalization from the plasma membrane or endocytic uptake from the extracellular medium, we next sought to determine whether the cytosolic class I pathway is used to generate Ld peptides for I-A^d binding. If this was the case, we predicted three experimental results: (a) a cytosolic form of Ld should
stimulate GTH; (b) expression of li should block binding of target L d peptide to I-A d and, as a result, inhibit stimulation of GTH; and (c) a cell line deficient in class I Ag presentation should not present the L d target peptide and, therefore, should not stimulate GTH.

To address the first hypothesis, we tested the ability of L cells expressing a cytosolic form of L d to stimulate GTH. A cytosolic form of L d (L d cyt) was generated using PCR mutagenesis of a cDNA of L d to remove the sequence encoding the leader peptide. An initiation sequence was then added 5' to the L d α1 domain. DAP-AD cells were transfected with genes encoding either L d cyt (DAP-ADLD cyt) or wild-type L d cDNA (DAP-ADLDc) in identical expression vectors. Unlike cells expressing wild-type L d, cells transfected with L d cyt were unable to stimulate GTH (Fig. 7 A). In addition, peptide dose–response curves for DAP-AD and DAP-ADLD cyt were virtually identical (Fig. 7 B) suggesting no appreciable presentation of the cytoplasmic L d target Ag. The inability of L d cyt to gain access to the appropriate processing compartment indicates that cytosolic subsets of Ld/Q10 or wild-type L d that fail to translocate normally into the ER are unlikely to serve as precursors for the processed peptide recognized.

Figure 6. (A) β-AD transfectants were incubated for 5 d in the presence (TNF/IFN-γ) or absence (M) of TNF (100 U/ml) and IFN-γ (10 U/ml) and then evaluated for MHC expression by flow cytometry. Two-step immunofluorescence staining was performed using the mAb 28.14.8 (anti-L α) or an irrelevant mAb (background fluorescence) followed by FITC-GAM. The resulting histograms are recorded as relative cell number vs mean fluorescence intensity. (B) β-AD does not present the endogenously derived determinant recognized by GTH, but effectively presents exogenously added Ld 61-85 peptide. APC were incubated at increasing cell numbers with 5 × 10^4 GTH T cells as previously described. (C–H) GTH responses to varying numbers of cytokine-treated β-AD APC; (■) responses to untreated APC. The GTH response to increasing concentrations of synthetic L d 61-85 peptide was evaluated using 5 × 10^5 cytokine-treated (◇) or untreated control (□) islet cell APC. (C and D) Untreated □ or treated (◇; TNF, 100 U/ml and IFN-γ, 10 U/ml for 4 d) islet cell APC were incubated with 5 × 10^4 54.8 T cells and increasing concentrations of OVA (C) or OVAT (D). (E–H) Untreated □ and treated (◇; TNF, 100 U/ml and IFN-γ, 10 U/ml for 5 d) DAP.3 transfectants were incubated in an Ag presentation assay with 5 × 10^4 cytokine-treated GTH (E and F) or 54.8 (G and H) T cells under the indicated conditions.
on the surface of DAP-ADLDcyl APC. The Ag presentation assay was performed using 5 \times 10^4 GTH T cells and an equal number of APC per well. Peptide was added at the indicated final concentrations at the initiation of the Ag presentation assay.

by GTH. Thus, unlike the results of Townsend et al. (52) in their analysis of class I-restricted presentation of a truncated cytosolic form of influenza hemagglutinin, these results argue that class II-restricted presentation of internally synthesized L\(^d\) does not occur via the cytosolic presentation pathway.

**Ii Expression Has No Effect on Presentation of L\(^d\) Peptide and Stimulation of GTH.** To test our second prediction, we examined the effect of Ii on Ag presentation. As a subset of L\(^d\) is poorly transported out of the ER (53), it seemed plausible that resident ER proteolytic machinery (54) might process L\(^d\) and generate peptides capable of binding newly synthesized class II molecules within the ER. Because experiments performed in vitro have demonstrated that Ii inhibits peptide binding to class II (16, 55, 56), we reasoned that ER presentation should be blocked in APC which express high levels of Ii. We therefore examined L\(^d\) peptide presentation by Ltk- APC transfected with I-A\(^d\) and L\(^d\) with and without genomic Ii (LADgli and LAD, respectively). As shown in Fig. 8 C, the Ii-positive and -negative APC stimulated GTH similarly, indicating that Ag presentation of L\(^d\) is independent of Ii expression.

**A Cell Line Deficient in Class I-restricted Ag Presentation Presents the Internally Synthesized L\(^d\) by MHC Class II.** To address whether L\(^d\) presentation is dependent on the functional TAP proteins which are important for class I Ag presentation, we examined the ability of a cell line deficient in MHC class I assembly (EE2H3) to stimulate GTH. EE2H3 is an H-2\(^k\) embryonic cell line that is deficient in the expres-

**Figure 8.** Ii expression does not affect the presentation of endogenous L\(^d\) target Ag. (A) Immunoprecipitation of LADgli-LD cell lysates demonstrates saturating levels of Ii in association with class II. Cells were labeled for 30 min with [\(^3\)H]leucine and Ii precipitated from the lysates with the mAbs IN-1 and P4H5 (lane 3), whereas I-A\(^d\) was precipitated using the mAb MKD6 (lane 2). The proteins were separated on SDS-10% PAGE under reducing conditions. (i) p31 and p41 Ii forms; (\(\rightarrow\)) \(\alpha\) and \(\beta\) chains. (Lane 1) Demonstrates precipitation with an irrelevant mAb for comparison of nonspecific background bands. (B) Flow cytometry of Ii- LAD-LD (a and b) and Ii- LADgli-LD (c and d) transfectants was performed as previously described. For a and c, cells were stained with the anti-class II mAb MKD6 (anti-I-A\(^d\), Ii-independent) and 40B (anti-I-A\(^d\), Ii-dependent) (39, 40). (b and d) Surface staining using the anti-L d mAbs 30.5.7 (Ii-independent) and 64.3.7 (Ii-dependent). (\(\rightarrow\)) Staining with an irrelevant mAb (14.4.4S, all panels). (C) Ii expression does not inhibit presentation of endogenous L\(^d\) to GTH. LAD and LADgli transfectants differing only in Ii expression were subsequently supertransfected with genomic L d yielding LAD-LD and LADgli-LD, respectively. These APC were then examined for their ability to stimulate GTH. Hybridomas were plated at 5 \times 10^4 cells/well with varying numbers of APC.
type resembling that of RMA-S (45, 57). EE2H3 was transfection with genes encoding L d and I-A d and the resulting transfectants (EE2H3-ADLD) tested for the ability to stimulate GTH. As shown in Fig. 9, EE2H3-ADLD effectively stimulated GTH despite near background levels of L d surface staining. In conjunction with the results described above, these data suggest that class II-restricted presentation of L d to GTH may not follow typical class I or II presentation pathways.

Discussion

Class II molecules are specialized to present peptides derived from exogenous Ag but are also capable of presenting peptides derived from proteins synthesized within the APC. Most of the studies addressing the mechanisms of class II Ag presentation have focused on the former (58, 59). These studies, in conjunction with those examining class II trafficking (60-62), the relationship between class II and Ii (16, 42, 55, 56), and the formation of stable class II dimers (63), have led to the general model that class II binds to peptides derived from Ag that enter the APC by endocytosis and are proteolyzed within acidic vesicles of the endosomal/lysosomal pathway. Clearly, internally synthesized secretory or integral membrane proteins theoretically have access to the putative endosomal/lysosomal processing pathway. However, it is becoming increasingly clear that internal Ag may access endosomes/lysosomes by mechanisms other than endocytosis, including chaperone-mediated trafficking from the cytosol, autophagy from the cytosol and ER, and direct trafficking from the TGN. It is less clear whether the route by which an Ag enters the endosomal/lysosomal pathway affects the repertoire of peptides revealed (64), or if different routes employ different processing cofactors. For example, prolonged Ag expression within the ER or Ag interaction with HSPs might influence processing such that the dominant epitopes generated are different from those revealed after endocytosis from the extracellular fluid.

We have established a model system designed to examine the mechanisms governing MHC class II presentation of an endogenous Ag. Unique to our system is the use of a target Ag (MHC class I, L d) that is constitutively expressed by a variety of nucleated cells, providing us with the opportunity to study the processing requirements for a normally expressed protein in cells of different lineages. T cells recognizing this epitope are stimulated by unmanipulated BALB/c splenocytes indicating that this peptide-class II complex is not only one which APC can be designed to generate, but is also one which is naturally displayed in vivo.

One possible explanation for the presentation of internally derived surface proteins by class II is that these proteins gain access to the endocytic pathway by internalization from the cell membrane. Using a secreted form of L d, we demonstrated that surface expression is not essential for L d presentation. Experiments using purified soluble L d/Q10 demonstrated that GTH was not stimulated even at Ag concentrations 1,000-fold greater than those present in the culture medium of DAP-ADLD/Q10 transfectants. Moreover, dm2 splenocytes, which include cells considered to be professional APC, were unable to present the exogenously added soluble form of L d. These results, coupled with those obtained in a series of coculture experiments, suggest that the secreted target Ag does not gain access to the class II presentation pathway by uptake from the extracellular milieu. We are confident that 4 d of coculture provided more than adequate time to accumulate MHC-peptide complexes at the cell surface because I-A d-positive APC transiently transfected with L d were
effective stimulators of GTH within 2 d of transfection (data not shown). The finding that soluble L^d/Q10 added to I-A^k-bearing APC resulted in the stimulation of a bulk population of CD4^+ anti-BALB/c T cells demonstrates that peptide determinants other than those recognized by GTH were generated from L^d/Q10. Attempts to modulate L^d processing and presentation with exogenously added anti-L^d antibody proved ineffective using APC expressing either the cell surface form of L^d or the secreted L^d/Q10 (data not shown). This is consistent with our hypothesis that a cell surface or extracellular intermediate is not involved in generating the L^d peptide recognized by GTH. Moreover EL4, a cell line defective in exogenous Ag presentation, effectively processed and presented internally synthesized L^d. Taken together, these data support the hypothesis that processing of L^d resulting in the peptide recognized by GTH takes place during biogenesis and intracellular transport of the target Ag.

Our experiments also address whether the L^d target Ag accesses class I proteolytic machinery within the cytosol. Transfection of APC with a cytosolic form of L^d did not result in stimulation of GTH. This is consistent with class II-restricted endogenous Ag presentation systems reported by Brooks et al. (10) and Weiss and Bogen (7), although several studies have indicated that cytosolic proteins may gain access to class II if they are expressed at very high levels (6, 8). Attempts to augment expression of L^d_{cyn} by increasing gene copy number in a transient transfection assay or by regulating expression with the strong β-actin promoter did not result in stimulation of GTH, nor was L^d_{cyn} presentation revealed by subjecting APC to serum starvation or heat shock (data not shown). These results suggest it is unlikely that improperly translocated L^d plays any role in stimulation of GTH. In support of this conclusion, transfectants of EE2H3 (45, 57), a cell line deficient in class I Ag presentation, effectively stimulated GTH. Finally, using three different cell types, we have found that L^d fails to block class II-restricted presentation of L^d. It is therefore improbable that the classical class I processing pathway generates the L^d peptide recognized by GTH.

One of the most intriguing results from this series of experiments relates to the differences observed between different cell types in exogenous and endogenous Ag presentation. A lymphoblast tumor cell line (EL4) defective in exogenous class II Ag presentation effectively stimulated GTH. In contrast, a pancreatic cell line (BTC-3) capable of exogenous Ag presentation, was unable to present endogenous L^d despite high surface expression of both the restriction element and the L^d target Ag. These results suggest that to generate and present the L^d peptide, it is insufficient to merely express the target Ag and the appropriate MHC class II restriction element. Taken together, our results suggest that different cofactors may regulate endogenous and exogenous class II Ag presentation and that expression of these cofactors may be regulated in a tissue-specific manner. This possibility is consistent with earlier work showing that some APC, differing in cell type or physiologic state, show differences in their ability to present epitopes derived from extracellular Ag (65, 66). Although the biological basis for the observed differences remains to be determined, our observations suggesting that different cell lines process and present Ag differently have potential implications for a number of immune phenomena including thymic selection, where different APC types are believed to be responsible for positive and negative selection, and autoimmune responses, where tissue-specific Ag presentation might play a role in the pathogenesis of localized, T cell-mediated autoimmune disease.

We thank J. Miller and J. Bluestone for critical reading of the manuscript; J. Miller, F. Fitch, J. Bluestone, A. Chervonsky, and E. Sercarz (University of California, Los Angeles) for cell lines used in these experiments; D. Margulies for providing the pl^d/Q10 construct and purified L^d/Q10; T. Hansen for providing the genomic L^d construct; M. Riley for assistance in establishing model system; E. Klotz for assistance in generating the L^d_{cyn} construct; H. Schreiber for providing TNF; D. Cronin for assistance in vivo T cell depletion experiments; and we are particularly grateful to Lisa Boyd for quantitative analysis of L^d/Q10 containing supernatant. Flow cytometry was performed in the University of Chicago Cancer Center Core Facility.

G. E. Loss is supported by a National Institutes of Health (NIH) Surgical Scientist Training Program grant (HL-07665). A. J. Sant is supported by grants from the NIH (PO1-CA14599 and PO1-CA19266) and from the Arthritis Foundation.

Address correspondence to Dr. A. J. Sant, Department of Pathology, Committee on Immunology, University of Chicago, 5841 S. Maryland, MC 1089, Chicago, IL 60637.

Received for publication 1 July 1992 and in revised form 6 April 1993.

References

1. Babbitt, B.P., P.M. Allen, G. Matsueda, E. Haber, and E.R. Unanue. Binding of immunogenic peptides to Ia histocompatibility molecules. 1985. Nature (Lond.), 317:359.

2. Townsend, A.R.M., J. Rothbard, F.M. Gotch, G. Bamadur, D. Wraith, and A.J. McMichael. 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be
20. McKenzie, I.F.C., G.M. Morgan, R.W. Melvold, and H.I. Kohn. 1977. BALB/c×H-2b: a new H-2 mutant in BALB/c and K/H-2b genetic backgrounds. J. Exp. Med. 148:2187.

21. Sant, A.J. 1993. Isotypic residues in the membrane proximal domain of HLA class II molecules control activation of CD4 positive T cells. J. Immunol. In press.

22. Shimonomotoki, R., J. Kappler, P. Marrack, and H. Grey. 1983. Antigen recognition by H-2 restricted T cells I. Cell-free antigen processing. J. Exp. Med. 158:303.

23. Kappler, J., B. Skidmore, J. White, and P. Marrack. 1981. Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridoma. J. Exp. Med. 153:1198.

24. Bhattacharya, A., M.E. Dorf, and T.A. Springer. 1981. A shared alloantigenic determinant on Ia antigens encoded by the I-A and I-E subregions: evidence for I region gene duplication. J. Immunol. 127:2488.

25. Koch, N., G.J. Hammerling, N. Tada, S. Kimura, and U. Hammerling. 1982. Cross-blocking studies with monoclonal antibodies against I-A molecules of haplotypes b, d, and k. Eur. J. Immunol. 12:909.

26. Piers, M., C. Devaux, M. Dosseto, and S. Marchetto. 1981. Clonal analysis of B- and T-cell responses to Ia antigens. Immunogenetics. 14:481.

27. Ohoto, K., N.M. Mayer, and D.H. Sachs. 1980. Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens. J. Immunol. 124:533.

28. Braunstein, N.S., and R.N. Germain. 1987. Allele-specific control of Ia molecule surface expression and conformation: implications for a general model of Ia structure-function relationships. Proc. Natl. Acad. Sci. USA. 84:2921.

29. Ohoto, K., T.H. Hansen, and D.H. Sachs. 1980. Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the product of a third polymorphic locus of the mouse major histocompatibility complex. J. Immunol. 125:2473.

30. Shirioishi, T., G.A. Evans, E. Appella, and K. Ozato. 1985. In vitro mutagenesis of a mouse MHC class I gene for the examination of structure-function relationships. J. Immunol. 134:623.

31. Staerz, U.D., H.-O. Rammensee, J.D. Benedetto, and M.J. Bevan. 1985. Characterization of a murine monodonal antibody specific for an allotypic determinant on T cell antigen receptor. J. Immunol. 124:3944.

32. Mehrtger, J.H., M.R. Harris, C.S. Kindle, D.W. McCourt, and S.E. Cullen. 1981. Characterization of fragments of the murine Ia-associated invariant chain. J. Immunol. 146:920.

33. Koch, N., S. Koch, and G.J. Hammerling. 1982. Ia invariant chain detected on lymphocyte surface by monoclonal antibody. Nature (Lond.). 299:644.

34. Sarmiento, M., A.L. Glasebrook, and F.W. Fitch. 1980. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolyis in the absence of complement. J. Immunol. 125:2665.

35. Dialynas, D.P., Z.S. Quan, K.A. Wall, A. Piers, J. Quintans, M.R. Loken, M. Piers, and F.W. Fitch. 1983. Characterization of the murine T cell surface molecule designated L3T4 identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol. 131:2445.

36. Coat, M., L. Boyd, and D.H. Margulies. 1992. Isolation and characterization of self peptides eluted from engineered soluble major histocompatibility antigens H-2Ld and H-2Dd. J. Cell Biol. 101:725.

37. Ribaud, R.K., and D.H. Margulies. 1992. Independent and...
synergistic effects of disulfide bond formation, \( \beta 2 \)-microglobulin, and peptides on class I MHC folding and assembly in an in vitro translation system. *J. Immunol.* 149:2935.

38. Gunning, P., J. Leavitt, G. Muscat, S-Y Ng, and L. Kedes. 1987. A human \( \beta 2 \)-actin expression vector system directs high-level accumulation of antisense transcripts. *Proc. Natl. Acad. Sci. USA.* 84:4831.

39. Kozak, M. 1987. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. *Nucleic Acids Res.* 15:8125.

40. Sant, A.J., N.S. Braunstein, and R.N. Germain. 1987. Predominant domain of amino-terminal sequences in dictating efficiency of class II major histocompatibility complex \( \alpha \beta \) dimer expression. *Proc. Natl. Acad. Sci. USA.* 84:8065.

41. Peterson, M., and J. Miller. 1992. The alternatively spliced, \( p 41 \), invariant chain gene product can enhance antigen presentation. *Nature (Lond.)* 357:596.

42. Anderson, M.S., and J. Miller. 1992. Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules. *Proc. Natl. Acad. Sci. USA.* 89:2282.

43. Efrat, S., S. Linde, H. Kofod, D. Spector, M. Delannoy, S. Grant, D. Hanehan, and S. Baekkeskov. 1988. Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene. *Proc. Natl. Acad. Sci. USA.* 85:9037.

44. Hartman, S.C., and R.C. Mulligan. 1988. Two dominant-acting selectable markers for gene transfer studies in mammalian cells. *Proc. Natl. Acad. Sci. USA.* 85:8047.

45. Silverman, T., A. Rein, B. Orrison, J. Langloss, G. Braththauer, J.-L. Miyazaki, and K. Ozato. 1988. Establishment of cell lines from somite stage mouse embryos and expression of major histocompatibility class I genes in these cells. *J. Immunol.* 140:4378.

46. Guagliardi, L.E., B. Koppelman, J.S. Blum, M.S. Marks, P. Grant, D.H. Fitch, D.E. Smilek, M. Sarmiento, and K.N. Pujol-Borrell, R., I. Todd, M. Dashi, G.F. Bottazzo, R. Sutton, D. Gray, G.R. Adolf, and M. Feldmann. 1987. HLA class II induction in human islet cells by IFN-\( \gamma \) plus tumor necrosis factor or lymphotixin. *Nature (Lond.)* 326:304.

47. Bikoff, E.K., L. Jaffe, R.K. Ribaudo, G.R. Otten, R.N. Germain, and E.J. Robertson. 1991. MHC class I surface expression in embryo-derived cell lines inducible with peptide or interferon. *Nature (Lond.)* 354:235.

48. Harding, C.V. 1991. Pathways of antigen processing. *Curr. Opin. Immunol.* 3:3.

49. Peters, P.J., and J.J. Neef~es. 1992. Intracellular transport is inducible with peptide or in vivo processing in intracellular HLA-DR molecules. *Proc. Natl. Acad. Sci. USA.* 89:83150.

50. Bikoff, E.K., L. Jaffe, R.K. Ribaudo, G.R. Otten, R.N. Germain, and E.J. Robertson. 1991. MHC class I surface expression in embryo-derived cell lines inducible with peptide or interferon. *Nature (Lond.)* 354:235.

51. Roche, P.A., and P. Cresswell. 1990. Invariant chain-associated HLA-DR molecules do not bind an immunologic peptide. *Nature (Lond.)* 345:615.

52. Roche, P.A., and P. Cresswell. 1991. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. *Proc. Natl. Acad. Sci. USA.* 88:3150.

53. Bikoff, E.K., L. Jaffe, R.K. Ribaudo, G.R. Otten, R.N. Germain, and E.J. Robertson. 1991. MHC class I surface expression in embryo-derived cell lines inducible with peptide or interferon. *Nature (Lond.)* 354:235.

54. Harding, C.V. 1991. Pathways of antigen processing. *Curr. Opin. Immunol.* 3:3.

55. Peters, P.J., and J.J. Neef~es. 1992. Intracellular transport is inducible with peptide or in vivo processing in intracellular HLA-DR molecules. *Proc. Natl. Acad. Sci. USA.* 89:83150.

56. Bikoff, E.K., L. Jaffe, R.K. Ribaudo, G.R. Otten, R.N. Germain, and E.J. Robertson. 1991. MHC class I surface expression in embryo-derived cell lines inducible with peptide or interferon. *Nature (Lond.)* 354:235.

57. Harding, C.V. 1991. Pathways of antigen processing. *Curr. Opin. Immunol.* 3:3.

58. Peters, P.J., J.J. Neef~es, V. Oorschot, H.I. Ploegh, and H.J. Geuze. 1991. Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. *Nature (Lond.)* 349:669.

59. Germain, R.N., and I.R. Hendrix. 1991. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. *Nature (Lond.)* 353:134.

60. Moreno, J., D.A.A. Vignali, F. Nadimi, S. Fuchs, L. Adorini, and G.J. Hammerling. 1991. Processing of an endogenous protein can generate MHC class II-restricted T cell determinants distinct from those derived from exogenous antigen. *J. Immunol.* 147:3306.

61. Panjwani, N., B. Malissen, and L. Hood. 1985. A-transfected L-cell fibroblasts present a lysozyme peptide but not the native protein to lysyme-specific T cells. *J. Immunol.* 82:5885.

62. Vidard, L., K.L. Rock, and B. Benacerraf. 1992. Heterogeneity in antigen processing by different types of antigen-presenting cells. Effect of cell culture on antigen processing ability. *J. Immunol.* 149:1905.